Nextcure Stock Price, News & Analysis

NextCure, Inc. (Nasdaq: NXTC) reported its third quarter 2020 financial results, highlighting ongoing clinical trials for NC318 and NC410. The company has $291.2 million in cash as of September 30, 2020, down from $334.6 million at the end of 2019, largely due to operational costs. R&D expenses increased to $12.7 million from $8.7 million year-over-year, while G&A expenses rose to $4.7 million from $2.6 million. Notably, there was no revenue this quarter, down from $1.6 million in Q3 2019, resulting in a net loss of $16.4 million, compared to $8.4 million last year.

NextCure, Inc. (Nasdaq: NXTC) appointed John G. Houston, Ph.D., to its board of directors on September 10, 2020. With over 30 years in the biotech sector, he currently serves as CEO of Arvinas, Inc. Dr. Houston's expertise in discovery biology and product development is expected to enhance NextCure's ongoing clinical trials for NC318 and NC410. Judith Li is stepping down from the board. The company focuses on developing first-in-class immunomedicines for cancer and immune-related diseases, utilizing its FIND-IO™ platform for novel treatment options.

NextCure, a clinical-stage biopharmaceutical company focused on immunomedicines for cancer and immune-related diseases, will present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on September 15 at 4:15 PM Eastern Time. The presentation will be accessible via a live audio webcast on NextCure's website, with a replay available for 30 days post-event. The company emphasizes its commitment to developing innovative therapies for patients unresponsive to existing treatments and relies on its FIND-IO platform for research and development.

NextCure, Inc. (NASDAQ: NXTC) reported its Q2 2020 financial results, revealing a net loss of $14.5 million compared to $8.2 million in Q2 2019. Cash reserves decreased to $309.3 million from $334.6 million in December 2019 due to operational costs. There was no revenue this quarter, a drop from $1.4 million last year. Despite setbacks in clinical trials for non-small cell lung and ovarian cancers, NextCure is encouraged by its ongoing trials for NC318 and has initiated the Phase 1 trial for NC410. Key milestones include patient enrollment in HNSCC and triple-negative breast cancer cohorts.

NextCure, a clinical-stage biopharmaceutical company focused on developing first-in-class immunomedicines for cancer and immune-related diseases, will present at the BTIG Virtual Biotechnology Conference on August 11 at 9:30 am ET. A live audio webcast will be accessible on NextCure's website, with a replay available two hours post-event and archived for 30 days. The company aims to address treatment gaps for patients unresponsive to current therapies through its proprietary FIND-IO™ platform.

NextCure (Nasdaq: NXTC) provided an interim update for its NC318 phase 2 trial, announcing that it will not advance the non-small cell lung cancer and ovarian cancer cohorts into stage 2 due to disappointing biomarker data. Ongoing evaluations will determine future studies in these areas. However, the head and neck cancer cohort has shown one confirmed partial response, allowing advancement to stage 2. The company expects to release further clinical data in Q4 2020. Additionally, Chief Medical Officer Kevin Heller has resigned, effective August 4, 2020, but will continue as a consultant.

NextCure, Inc. (Nasdaq: NXTC) announced the initiation of a Phase 1/2 clinical trial for NC410, targeting immune suppression mediated by LAIR-1. This open-label trial aims to evaluate the safety, tolerability, and dosage of NC410 in patients with advanced solid tumors. The trial's Phase 1 results are expected by the second half of 2021. This marks a significant advancement in NextCure's pipeline, as it is the first company to explore LAIR proteins clinically. The firm aims to provide new treatment options for patients unresponsive to existing therapies.

NextCure, Inc. (NXTC) reported Q1 2020 results, highlighting a significant revenue increase to $22.4 million, up from $1.4 million in Q1 2019, primarily due to recognition of deferred revenue from a terminated agreement with Eli Lilly. Cash, cash equivalents, and marketable securities totaled $322.1 million. However, the company faced challenges as the COVID-19 pandemic delayed the initiation of the NC410 clinical trial and other milestones. R&D expenses rose to $10.6 million, reflecting expanded clinical activities. Notably, net income reached $9.7 million, compared to a $6.2 million loss in the prior year.

NextCure (Nasdaq: NXTC), a clinical-stage biopharmaceutical company, will present at the BofA Securities Virtual Health Care Conference on May 13th at 9:00 am Eastern time. The event will be accessible via a live audio webcast on the company's website, with a replay available two hours post-event for 30 days. NextCure focuses on developing innovative immunomedicines for cancer and immune-related diseases using its proprietary FIND-IO™ platform.